

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CK Life Sciences Int'l. (Holdings) Inc.

長 江 生 命 科 技 集 團 有 限 公 司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 0775)

PROFIT WARNING

This announcement is made pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the “Board”) of CK Life Sciences Int'l. (Holdings) Inc. (the “Company” and together with its subsidiaries, the “Group”) wishes to inform shareholders of the Company (the “Shareholders”) that based on the preliminary review of the Group's unaudited consolidated management accounts for the six months ended 30 June 2025 (the “Management Accounts” and the “Reporting Period”, respectively) and the information that is currently available to the Board, the Group expects to report a loss attributable to Shareholders of around HK\$150 million for the Reporting Period compared to a profit of HK\$1 million in the corresponding period in 2024. The change from profit to loss is attributable to the Company's planned decision to increase R&D investments. Overall, the operations of the Group remained stable throughout the Reporting Period and up to the date of this announcement. Further details will be disclosed in the interim results announcement of the Company to be published on 12 August 2025.

The Company is still in the process of finalising the financial results of the Group for the Reporting Period. The information contained in this announcement is only based on the preliminary review and analysis of the Management Accounts and the information currently available to the Board and is not based on any figures or information audited by the Company's independent auditor or reviewed by the audit committee of the Board and may be subject to change. The Shareholders and potential investors are advised to read carefully the interim results announcement of the Company to be published on 12 August 2025.

Shareholders and potential investors are advised to exercise caution when dealing in the shares and other securities of the Company.

By Order of the Board
CK Life Sciences Int'l. (Holdings) Inc.
Eirene Yeung
Company Secretary

Hong Kong, 31 July 2025

As at the date of this announcement, the Executive Directors of the Company are Mr. Li Tzar Kuoi, Victor (Chairman), Mr. Kam Hing Lam, Mr. Ip Tak Chuen, Edmond, Mr. Yu Ying Choi, Alan Abel, Mr. Lance Richard Lee Yuen and Dr. Toh Kean Meng, Melvin; and the Non-executive Directors are Mr. Peter Peace Tulloch, Mrs. Kwok Eva Lee (Independent Non-executive Director), Mr. Kwan Kai Cheong (Independent Non-executive Director), Mr. Paul Joseph Tighe (Independent Non-executive Director) and Mr. Donald Jeffrey Roberts (Independent Non-executive Director).